filmov
tv
Johnson & Johnson CFO talks Q2 earnings, medtech business
Показать описание
Johnson & Johnson (JNJ) reported second-quarter earnings that beat estimates on both revenue and profit. The company posted revenue of $22.45 billion, surpassing the expected $22.34 billion, while adjusted EPS came in at $2.82, above the projected $2.71. Despite this strong performance, JNJ lowered its full-year guidance, citing impacts from recent acquisitions.
Johnson & Johnson CFO Joe Wolk joins Yahoo Finance health reporter Anjalee Khemlani to discuss the results.
Wolk expresses satisfaction with the company's top-line growth in the second quarter, noting expansion across various business segments and products. While acknowledging that its medtech segment's sales fell slightly short of expectations, he details the company's growth plans for this sector moving forward.
Wolk highlights the recent acquisition of Abiomed, describing it as "a nice complement" that strengthens JNJ's position in the cardiovascular space. "I think we're very well positioned to play in these higher growth markets," Wolk states, remaining optimistic about the medtech business' potential despite the quarter's disappointing performance.
"Continuing to come up with new innovative medicines that raise the standard of care is really what is the formula for our success," Wolk tells Yahoo Finance.
#news #youtube #pharmaceutical
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Follow Yahoo Finance on social:
Johnson & Johnson CFO Joe Wolk joins Yahoo Finance health reporter Anjalee Khemlani to discuss the results.
Wolk expresses satisfaction with the company's top-line growth in the second quarter, noting expansion across various business segments and products. While acknowledging that its medtech segment's sales fell slightly short of expectations, he details the company's growth plans for this sector moving forward.
Wolk highlights the recent acquisition of Abiomed, describing it as "a nice complement" that strengthens JNJ's position in the cardiovascular space. "I think we're very well positioned to play in these higher growth markets," Wolk states, remaining optimistic about the medtech business' potential despite the quarter's disappointing performance.
"Continuing to come up with new innovative medicines that raise the standard of care is really what is the formula for our success," Wolk tells Yahoo Finance.
#news #youtube #pharmaceutical
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Follow Yahoo Finance on social:
0:11:03
Johnson & Johnson CFO talks earnings, vaccines
0:07:58
Johnson & Johnson CFO talks Q2 earnings, medtech business
0:56:19
A Conversation with Johnson & Johnson CFO Joe Wolk
0:08:45
Johnson & Johnson CFO: How inflation plays out is ‘anybody’s guess’
0:10:05
Johnson & Johnson CFO on why the company is splitting into 2 separate companies
0:06:19
Johnson & Johnson CFO Talks Capital Commitments and Acquisitions | Bloomberg Talks
0:07:44
Johnson & Johnson Confident on Covid Vaccine Trial Despite Pause: CFO
0:04:45
Johnson & Johnson CFO Dominic Caruso: We Price Our Products Responsibly | CNBC
0:40:40
Ford CFO Reveals SHOCKING Truth About Tariffs, EV Strategy, & Rare Earth Crisis!
0:07:02
Johnson & Johnson CFO discusses earnings, profit forecast, vaccines, and talcum powder lawsuits
0:08:37
Johnson & Johnson CFO Joseph Wolk Talks Earnings | Bloomberg Talks
0:06:12
Watch CNBC's full interview with Johnson & Johnson CFO Joseph Wolk
0:08:14
Coronavirus vaccine: Johnson and Johnson CFO discusses phase 1 trial, human testing, plus earnings
0:07:57
COVID vaccine 'on track' after blood clot scare: Johnson & Johnson CFO
0:33:41
Instacart CFO Talks Growth, Leadership & Strategy | J.P. Morgan Global TMT Conference 2025
0:08:23
Johnson and Johnson CFO discusses company earnings and pending lawsuits
0:07:29
Johnson & Johnson Expects Tariffs to Cost Company $400 Million
0:03:41
Johnson & Johnson CFO breaks down mixed earnings report, full-year guidance
0:11:03
J&J CFO addresses talcum powder and opioid lawsuits
0:32:56
Southwest Airlines CFO Talks Major Changes, Basic Economy, and $1.8B EBIT Plan | Wolfe Conference 20
0:10:14
Pepsico CFO talks earnings, inflation, price hikes, and company outlook
0:10:09
We’ll have about 600-800 million coronavirus vaccines available in early 2021: Johnson & Johnson...
0:07:05
J&J Aims to Achieve 1 Billion Covid Vaccines, CFO Says
0:04:16
J&J CFO on Q1 earnings beat, Covid vaccine pause in U.S.
Комментарии